All lectures are on Tuesdays from 12 to 1 p.m. in Comer Commons at Moores Cancer Center (directions and map). Lunch is available at 11:45 a.m. for those attending the lecture.
Principles of Cancer Drug Therapeutics Development
This is a series of weekly lectures delivered by CT2 and UC San Diego faculty members focusing on the necessary sequential steps involved in drug development.
Topics in Cancer Drug Development
This is a series of lectures by industry leaders in cancer drug development. The goal is to expose trainees to experts with a substantial track record in the “real life” challenges of cancer drug development. The lecturers are typically CEOs, directors of research, or medical directors from companies in the San Diego biomedical community, although experts from large pharmaceutical companies have also participated. The outside speakers are invited to discuss challenges of developing a given target or novel therapeutic and give fellows an opportunity to hear the story of the development of specific therapeutic agents.
|1/08/19||Silvio Gutkind, PhD||UCSD||Targeting the mTOR and Hippo Signaling Networks for Cancer Prevention and Treatment|
|1/15/19||James Murphy, MD||UCSD||Intersection of Observational and Translational Research in Oncology|
|1/22/19||Greg Daniels, MD||UCSD||Melanoma and Nonmelanoma Skin Cancer Immune Therapy|
|1/29/19||Gary Palmer, MD, JD, MBA, MPH||Chief Medical Officer, Tempus||Precision Medicine: The Value of Combined Clinical and Genomic Data|
|2/05/19||Nicole Steinmetz, PhD||UCSD||NanoEngineering Gone Viral|
|2/12/19||Ryan Dittamore, MBA||Epic Biosciences||Clinical Validation of Single CTC Profiling as a Predictive Biomarker of Treatment Selection in mCRPC|
|2/19/19||Laure Escoubet, PhD||Celgene||Epigenetic Discovery in Industry|
|2/26/19||Andrew Lowy, MD||UCSD||TBD|
|3/05/19||Danielle James, MD||Pharmacyclics||TBD|
|3/12/19||Yi Lui, PhD||Wellspring Biosciences||Targeting KRAS Mutant Cancers with a Covalent G12C-specific Inhibitor|
|3/26/19||Richard Schwab, MD||UCSD||Targeted Therapy for Breast Cancer|
|4/16/19||Chris Counter, PhD||Duke||TBD|
|4/23/19||Karen Messer, PhD||UCSD||Design of Phase I and II Clinical Trials|
|4/30/19||Katelyn McCabe- Willis, PhD||InhibRx||TBD|
|5/07/19||Tannishtha Reya, PhD||UCSD||New Models for Imaging Cancer Stem Cells and Therapy Resistance in Real Time|
|5/14/19||Richard Klemke, PhD||UCSD||TBD|
Schedules for previous years